COVID-19, Meme Kanseriyle İlişkili Lenfödemde Kompleks Dekonjestif Fizyoterapinin Etkinliğini Azaltabilir: Olgu Sunumu

Öz

Tedavi sürecinde COVID-19 tanısı alan meme kanseriyle ilişkili lenfödemi olan bir hastanın tedavi sonuçları sunulmaktadır. Kırk yedi yaşındaki kadın hastanın tek taraflı meme kanseriyle ilişkili lenfödemi vardı. Hasta, COVID-19 tanısından önce ve COVID- 19'dan iyileştikten sonra sırasıyla 10 ve 15 seans kompleks dekonjestif fizyoterapi tedavisi aldı. Uzuv hacmi, çevre ölçümüne dayalı olarak frustum formülü kullanılarak hesaplandı. Etkilenmiş uzuvda ağrı şiddetinin seviyesi, 11 puanlık sayısal ağrı değerlendirme ölçeği kullanılarak değerlendirildi. COVID-19 tanısından önce hastada ağrı yoktu ve uzuv hacmi kompleks dekonjestif fizyoterapi sonrasında %61 azaldı. Hasta, COVID-19'dan iyileştikten hemen sonra kolunda ağrı skoru 8'di. Uzuv hacmi, 10. ve 15. seanslar sonunda sırasıyla %3 ve %17 azalmıştı. Ağrı skorları, 10. ve 15. seanslar sonunda sırasıyla 4 ve 0'dı. COVID-19 geçirmiş meme kanseriyle ilişkili lenfödemi olan hastalarda kompleks dekonjestif fizyoterapinin uzuv hacmi üzerindeki etkisi azalabilir. Bu hasta popülasyonunda kompleks dekonjestif fizyoterapiden en iyi sonuçları elde etmek için klinisyenlerin tedavi süresini belirlerken ve tedavinin etkinliğini değerlendirirken hastanın COVID-19 durumunu veya ilgili tıbbi geçmişini dikkate almaları önerilir.

Anahtar Kelimeler

• Meme neoplazmı
• COVID-19
• Lenfödem
• Ağrı

COVID-19 May Reduce the Effectiveness of Complex Decongestive Physiotherapy in Breast Cancer-Related Lymphedema: A Case Report

Öz

The results of treatment for a patient with breast cancer-related lymphedema who was diagnosed with COVID-19 in a treatment period are presented. A 47-year-old female patient had unilateral breast cancer-related lymphedema. The patient received complex decongestive physiotherapy for 10 and 15 sessions before COVID-19 diagnosis and after the patient recovered from COVID-19, respectively. The limb volume was calculated using the frustum formula, relying on arm circumference measurements. The level of pain severity on the affected limb was assessed using an 11-point numeric pain rating scale. Before COVID-19 diagnosis, the patient had no pain, and the limb volume of the patient decreased by about 61% after complex decongestive physiotherapy. After the patient recovered from COVID-19, the patient had a pain score of 8 on her affected limb. The limb volume decreased by about 3% and 17% at the end of the 10th and 15th sessions, respectively. The pain scores were 4 and 0 at the end of the 10th and 15th sessions, respectively. The effectiveness of complex decongestive physiotherapy in limb volume may be reduced in patients with breast cancer-related lymphedema who have experienced COVID-19. To achieve optimal results from complex decongestive physiotherapy in this patient population, clinicians are advised to consider the patient's COVID-19 status or relevant medical history when determining the treatment duration and assessing the effectiveness of the treatment.

Anahtar Kelimeler

• Breast neoplasm
• COVID-19
• Lymphedema
• Pain

Kaynakça

1. Yang L, Liu S, Liu J, Zhang Z, Wan X, Huang B, et al. COVID-19: immunopathogenesis and Immunotherapeutics. Signal Transduct Target Ther. 2020;5(1):128.
2. Bian XW, COVID-19 Pathology Team. Autopsy of COVID-19 patients in China. Natl Sci Rev. 2020;7(9):1414–1418.
3. Lawenda BD, Mondry TE, Johnstone PAS. Lymphedema: A primer on the identification and management of a chronic condition in oncologic treatment. CA Cancer J Clin. 2009;59(1):8–24.
4. Executive Committee of the International Society of Lymphology. The diagnosis and treatment of peripheral lymphedema: 2020 consensus document of the international society of lymphology. Lymphology. 2020;53(1):3–19.
5. Sander AP, Hajer NM, Hemenway K, Miller AC. Upper-extremity volume measurements in women with lymphedema: a comparison of measurements obtained via water displacement with geometrically determined volume. Phys Ther. 2002;82(12):1201–1212.
6. Mayrovitz HN. The standard of care for lymphedema: current concepts and physiological considerations. Lymphat Res Biol. 2009;7(2):101–108.
7. Armer JM, Radina ME, Porock D, Culbertson SD. Predicting breast cancer-related lymphedema using self-reported symptoms. Nurs Res. 2003;52(6):370–379.
8. Wanchai A, Armer JM, Stewart BR, Lasinski BB. Breast cancer-related lymphedema: A literature review for clinical practice. IJNSS. 2016;3(2):202–207.

9. Ciotti M, Ciccozzi M, Terrinoni A, Jiang WC, Wang CB, Bernardini S. The COVID-19 pandemic. Crit Rev Clin Lab Sci. 2020;57(6):365–388.
10. Juhel BC, Brunelle CL, Bernstein MC, Smith LH, Jung AW, Ababneh HS, et al. Side effects of COVID-19 vaccinations in patients treated for breast cancer. Clin Exp Med. 2023; 1–10.